Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 681-694

  von Websky, Karoline ^a   Reichetzeder, Christoph ^a   Hocher, Berthold ^a  

^a UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Glycemic control; Hypoglycemia; Incretin; Renal impairment

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ELDERLY CARE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IC 50; INSULIN TREATMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; QUALITY OF LIFE; REVIEW; SEVERE RENAL IMPAIRMENT;

DIPEPTIDYL PEPTIDASE-4; GLUCAGON LIKE PEPTIDE-1; GLYCEMIC CONTROL; HYPOGLYCEMIA; INCRETIN; RENAL IMPAIRMENT;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT SELECTION; PURINES; QUINAZOLINES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84889833566     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S40035     Document Type: Review

References (102)

1. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237-244.
2. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. Epub 2013 Aug 13.
3. Yki-Jarvinen H, Rosenstock J, Duran-Garcia S, et al. Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥ 52-week randomized, double-blind study. Diabetes Care. 2013. Epub 2013 Sep 23.
4. Sarwar N, Gao P, Seshasai SR, et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed July 11, 2013.
6. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36 Suppl 1:S11-S66.
7. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
8. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
9. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-835.
10. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
11. National Institute for Health and Clinical Excellence. Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. London: National Institute for Health and Clinical Excellence; 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/CG87ShortGuideline.pdf. Accessed May 29, 2013.
12. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
13. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29(3):504-509.
14. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501-506.
15. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
16. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27(11):2597-2602.
17. Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008;10(12): 1212-1220.
18. Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med. 1988;108(3):334-340.
19. Ahrén B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care. 2003;26(10):2860-2864.
20. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13 Suppl 1:89-94.
21. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol. 2012;214(3):381-387.
22. Akarte AS, Srinivasan BP, Gandhi S. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Biochem Pharmacol. 2012;83(2):241-252.
23. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):186-193.
24. Bosi E. Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab. 2010;95(6):2607-2609.
25. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
26. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33(5):511-527.
27. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57-64.
28. diabetes.org [homepage on the Internet]. ADA/EASD/IDF Statement concerning the use of incretin therapy and pancreatic disease [ADA news release]. American Diabetes Association; 2013 [updated June 28, 2013; cited July 10, 2013]. Available from: http://www.diabetes.org/for-media/2013/recommendations-for.html. Accessed September 25, 2013.
29. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45(7): 937-948.
30. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103-3109.
31. Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab. 2011;13(3):193-203.
32. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127-1142.
33. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648-658.
34. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175-182.
35. Tradjenta® (linagliptin) tablets [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2011.
36. fda.gov [homepage on the internet]. Tradjenta (linagliptin) Prescribing Information September 2012; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201280s005lbl.pdf. Accessed October 9, 2013.
37. Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(5):470-478.
38. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19(1):133-140.
39. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
40. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148-1155.
41. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167-177.
42. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513-523.
43. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667-678.
44. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1): 7-18.
45. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13(10):939-946.
46. Plantinga LC, Crews DC, Coresh J, et al; CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673-682.
47. Friedrich C, Emser A, Woerle H-J, Graefe-Mody U. Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes. Am J Ther. 2013. Epub 2013 Feb 13
48. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013;6:161-170.
49. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol. 2003;43(3):252-259.
50. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545-555.
51. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230-1239.
52. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13(1):4-8.
53. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947-954.
54. Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012;303(7):F963-F971.
55. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36(1):119-130.
56. Groop PH, Cooper M, Perkovic V, et al. Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy. Abstract and poster presented at the 72nd Scientific Sessions of the American Diabetes Association; June 8-12; 2012; Philadelphia, PA.
57. Boehringer Ingelheim Pharmaceutic. MARLINA: efficacy, safety and modification of albuminuria in type 2 diabetes subjects with renal disease with linagliptin. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01792518. NLM identifier: NCT01792518. Accessed May 29, 2013
58. Fagot-Campagna A, Bourdel-Marchasson I, Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab. 2005;31 Spec No 2:S535-S552.
59. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36.
60. Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care. 1997;20(2):135-141.
61. Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9: 155-163.
62. Bauduceau B, Doucet J, Bordier L, Garcia C, Dupuy O, Mayaudon H. Hypoglycaemia and dementia in diabetic patients. Diabetes Metab. 2010;36 Suppl 3:S106-S111.
63. Woehrle HJ, Neubacher D, Patel S, von Eynatten M. Safety and efficacy of linagliptin plus basal insulin combination therapy in a vulnerable population of elderly patients (age ≥70 years) with type 2 diabetes. Poster presented at the 48th Annual Meeting of the European Association for the Study of Diabetes; October 1-5; 2012; Berlin, Germany.
64. Patel S, Schernthaner G, Barnett AH, Emser A, von Eynatten M, Woerle HJ. Safety and efficacy of linagliptin in elderly patients with type 2 diabetes: evidence from 1331 individuals aged ≥65 years [abstract]. Diabetologia. 2012;55(Suppl 1):S351.
65. Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther. 2012;29(3):218-233.
66. Gore MO, McGuire DK. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res. 2009;6(1):53-55.
67. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens. 2005;19 Suppl 1:S27-S32.
68. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
69. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
70. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33(6):1389-1394.
71. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
72. Jørgensen CH, Gislason GH, Andersson C, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.
73. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174(2):169-174.
74. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, MD: US Department of Health and Human Services; 2008. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed September 25, 2013.
75. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3.
76. von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol. 2013;12:60.
77. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483.
78. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16-27.
79. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
80. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485-494.
81. Boehringer Ingelheim Pharmaceuticals. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01243424?term=NCT01243424&rank=1. NLM identifier: NCT01243424. Accessed May 29, 2013.
82. Takeda Global Research and Development Center, Inc. Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE). Available from: http://clinicaltrials.gov/ct2/show/NCT00968708?term=NCT00968708&rank=1. NLM identifier: NCT00968708. Accessed May 29, 2013.
83. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6.
84. Amylin Pharmaceuticals, LLC. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01144338?term=ExenatideStudyofCardiovascularEventLoweringTrial(EXSCEL)&rank=1. NLM identifier: NCT01144338. Accessed May 29, 2013.
85. Novo Nordisk. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results-a long term evaluation (LEADER®). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01179048?term=LiraglutideEffectandActioninDiabets(LEADER)&rank=1. NLM identifier: NCT01179048. Accessed May 29, 2013.
86. Bhatt DL; SAVOR TIMI 53 Steering Committee and Investigators. Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 study. Presented at the European Society of Cardiology Congress; August 30-September 3; 2013; Amsterdam, The Netherlands. Available from: http://www.escardio.org/about/press/esc-congress-2013/press-conferences/Documents/slides/bhatt.pdf. Accessed September 25, 2013.
87. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol. 2013;167(1): 87-93.
88. Chaykovska L, von Websky K, Rahnenführer J, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011;6(11):e27861.
89. Shah ND, Mullan RJ, Breslin M, Yawn BP, Ting HH, Montori VM. Translating comparative effectiveness into practice: the case of diabetes medications. Med Care. 2010;48(Suppl 6):S153-S158.
90. Spencer MS, Kieffer EC, Sinco BR, et al. Diabetes-specific emotional distress among African Americans and Hispanics with type 2 diabetes. J Health Care Poor Underserved. 2006;17(Suppl 2):88-105.
91. Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
92. Boehringer Ingelheim Pharmaceuticals. Safety and efficacy in type 2 diabetic patients with severe chronic renal impairment, 5 mg BI 1356 (Linagliptin) vs placebo, insulin background inclusive. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00800683?term=NCT00800683&rank=1. NLM identifier: NCT00800683. Accessed May 29, 2013.
93. Boehringer Ingelheim Pharmaceuticals. Efficacy and safety of linagliptin in elderly patients with type 2 diabetes. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01084005?term=NCT01084005&rank=1. NLM identifier: NCT01084005. Accessed May 29, 2013.
94. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635.
95. Lewin A, Lipetz R, Wu J, Schwartz S. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. Clin Ther. 2007;29(5):844-855.
96. ONGLYZA® (saxagliptin) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
97. JANUVIA® (sitagliptin) tablets [package insert]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp; 2006.
98. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(3):252-257.
99. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145-1152.
100. Inzucchi SE, Nauck M, von Eynatten M, Hehnke U, Woerle HJ, Henry R. Lower risk of hypoglycemia in elderly type 2 diabetes patients when linagliptin is added to basal insulin: an exploratory analysis. Poster presented at the 73nd Scientific Sessions of the American Diabetes Association; June 21-25, 2013; Chicago, IL.
101. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236-1243.
102. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.